1. Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg. 2011 May;114(5):1369–79.
2. Vroonen L, Daly AF, Beckers A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology. 2019;109(1):20–7.
3. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8(1):43–52.
4. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001 Nov;86(11):5256–61.
5. Molitch ME. Dopamine resistance of prolactinomas. Pituitary. 2003;6(1):19–27.